CTOs on the Move

NeuBase Therapeutics

www.neubasetherapeutics.com

 
NeuBase is developing ultra precision genetic medicines targeting rare, monogenic diseases, therapeutic candidates for the treatment of myotonic dystrophy type 1 (DM1), Huntington`s disease (HD), and cancer-driving point mutations in KRAS G12V and G12D, which are involved in many tumor types and have historically been “undruggable.” for which there are no approved therapies, as well as more common genetic disorders, including cancers that are resistant to current therapeutic approaches. NeuBase`s pipeline includes
  • Number of Employees: 25-100
  • Annual Revenue: $1-10 Million

Executives

Name Title Contact Details
Anthony Rossomando
 Chief Technology Officer Profile

Similar Companies

biosynexus

Biosynexus understands that bringing a new pharmaceutical product to market is a complicated process that involves not only having strong research and development capabilities, but also having deep clinical development, manufacturing and marketing

Embecta

Embecta will be the name of the independent, publicly-traded company that will hold BD`s Diabetes Care business

Kyra Medical

KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Clean™ Stirrups A fabric-free stirrup to improve infection control. LEARN MORE KYRA® Curve™ Spine Frame The KYRA Curve has a class-...

I Holland Americas

I Holland Americas is a Fort Myers, FL-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

bellatrx

bellatrx is a Pointe-Claire, QC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.